200 related articles for article (PubMed ID: 31595301)
1. Analysis of Pharmacovigilance Databases for Dolutegravir Safety in Pregnancy.
van De Ven NS; Pozniak AL; Levi JA; Clayden P; Garratt A; Redd C; Mofenson LM; Hill A
Clin Infect Dis; 2020 Jun; 70(12):2599-2606. PubMed ID: 31595301
[TBL] [Abstract][Full Text] [Related]
2. Optimizing responses to drug safety signals in pregnancy: the example of dolutegravir and neural tube defects.
Mofenson LM; Pozniak AL; Wambui J; Raizes E; Ciaranello A; Clayden P; Ehrenkranz P; Fakoya A; Hill A; Khoo S; Mahaka I; Modi S; Moore C; Phillips A; Siberry G; Sikwese K; Thorne C; Watts HD; Doherty M; Ford NP
J Int AIDS Soc; 2019 Jul; 22(7):e25352. PubMed ID: 31298496
[TBL] [Abstract][Full Text] [Related]
3. Is There a Safety Signal for Dolutegravir and Integrase Inhibitors During Pregnancy?
Chouchana L; Beeker N; Treluyer JM
J Acquir Immune Defic Syndr; 2019 Aug; 81(4):481-486. PubMed ID: 31021990
[TBL] [Abstract][Full Text] [Related]
4. Dolutegravir and pregnancy outcomes in women on antiretroviral therapy in Brazil: a retrospective national cohort study.
Pereira GFM; Kim A; Jalil EM; Fernandes Fonseca F; Shepherd BE; Veloso VG; Rick F; Ribeiro R; Pimenta MC; Beber A; Corrêa RG; Lima R; Maruri F; McGowan CC; Schwartz Benzaken A; Grinsztejn B; Castilho JL;
Lancet HIV; 2021 Jan; 8(1):e33-e41. PubMed ID: 33387477
[TBL] [Abstract][Full Text] [Related]
5. Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study.
Dugdale CM; Ciaranello AL; Bekker LG; Stern ME; Myer L; Wood R; Sax PE; Abrams EJ; Freedberg KA; Walensky RP
Ann Intern Med; 2019 May; 170(9):614-625. PubMed ID: 30934067
[TBL] [Abstract][Full Text] [Related]
6. Neural-Tube Defects and Antiretroviral Treatment Regimens in Botswana.
Zash R; Holmes L; Diseko M; Jacobson DL; Brummel S; Mayondi G; Isaacson A; Davey S; Mabuta J; Mmalane M; Gaolathe T; Essex M; Lockman S; Makhema J; Shapiro RL
N Engl J Med; 2019 Aug; 381(9):827-840. PubMed ID: 31329379
[TBL] [Abstract][Full Text] [Related]
7. Dolutegravir-induced neural tube defects in mice are folate responsive.
Tukeman GL; Wei H; Lin YL; Wlodarczyk BJ; Finnell RH; Cabrera RM
AIDS; 2024 Mar; 38(4):439-446. PubMed ID: 37382903
[TBL] [Abstract][Full Text] [Related]
8. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study.
Zash R; Jacobson DL; Diseko M; Mayondi G; Mmalane M; Essex M; Gaolethe T; Petlo C; Lockman S; Holmes LB; Makhema J; Shapiro RL
Lancet Glob Health; 2018 Jul; 6(7):e804-e810. PubMed ID: 29880310
[TBL] [Abstract][Full Text] [Related]
9. Risk of birth defects and perinatal outcomes in HIV-infected women exposed to integrase strand inhibitors during pregnancy.
Sibiude J; Le Chenadec J; Mandelbrot L; Dollfus C; Matheron S; Lelong N; Avettand-Fenoel V; Brossard M; Frange P; Reliquet V; Warszawski J; Tubiana R;
AIDS; 2021 Feb; 35(2):219-226. PubMed ID: 33048878
[TBL] [Abstract][Full Text] [Related]
10. The Brazilian experience of implementing the active pharmacovigilance of dolutegravir.
Batista CJB; Correa RG; Evangelista LR; Fleck K; Silva L; Renaud F; Vitoria M; Doherty M; Benzaken AS
Medicine (Baltimore); 2019 Mar; 98(10):e14828. PubMed ID: 30855509
[TBL] [Abstract][Full Text] [Related]
11. Two cases of neural tube defects with dolutegravir use at conception in south Brazil.
Kreitchmann R; Oliveira FR; Sprinz E
Braz J Infect Dis; 2021; 25(2):101572. PubMed ID: 33852885
[TBL] [Abstract][Full Text] [Related]
12. Dolutegravir in pregnant mice is associated with increased rates of fetal defects at therapeutic but not at supratherapeutic levels.
Mohan H; Lenis MG; Laurette EY; Tejada O; Sanghvi T; Leung KY; Cahill LS; Sled JG; Delgado-Olguín P; Greene NDE; Copp AJ; Serghides L
EBioMedicine; 2021 Jan; 63():103167. PubMed ID: 33341441
[TBL] [Abstract][Full Text] [Related]
13. Neural Tube Defects in Pregnancies Among Women With Diagnosed HIV Infection - 15 Jurisdictions, 2013-2017.
Reefhuis J; FitzHarris LF; Gray KM; Nesheim S; Tinker SC; Isenburg J; Laffoon BT; Lowry J; Poschman K; Cragan JD; Stephens FK; Fornoff JE; Ward CA; Tran T; Hoover AE; Nestoridi E; Kersanske L; Piccardi M; Boyer M; Knapp MM; Ibrahim AR; Browne ML; Anderson BJ; Shah D; Forestieri NE; Maxwell J; Hauser KW; Obiri GU; Blumenfeld R; Higgins D; Espinet CP; López B; Zielke K; Jackson LP; Shumate C; Russell K; Lampe MA
MMWR Morb Mortal Wkly Rep; 2020 Jan; 69(1):1-5. PubMed ID: 31917782
[TBL] [Abstract][Full Text] [Related]
14. Gestational diabetes in women living with HIV in Botswana: lower rates with dolutegravir- than with efavirenz-based antiretroviral therapy.
Mmasa KN; Powis K; Sun S; Makhema J; Mmalane M; Kgole S; Masasa G; Moyo S; Gerschenson M; Mohammed T; Legbedze J; Abrams EJ; Kurland IJ; Geffner ME; Jao J
HIV Med; 2021 Sep; 22(8):715-722. PubMed ID: 34003565
[TBL] [Abstract][Full Text] [Related]
15. Dolutegravir and pregnancy outcomes including neural tube defects in the USA during 2008-20: a national cohort study.
Kourtis AP; Zhu W; Lampe MA; Huang YA; Hoover KW
Lancet HIV; 2023 Sep; 10(9):e588-e596. PubMed ID: 37506721
[TBL] [Abstract][Full Text] [Related]
16. Comparison between paediatric and adult suspected adverse drug reactions reported to the European medicines agency: implications for pharmacovigilance.
Blake KV; Zaccaria C; Domergue F; La Mache E; Saint-Raymond A; Hidalgo-Simon A
Paediatr Drugs; 2014 Aug; 16(4):309-19. PubMed ID: 24898717
[TBL] [Abstract][Full Text] [Related]
17. Engendering health systems in response to national rollout of dolutegravir-based regimens among women of childbearing potential: a qualitative study with stakeholders in South Africa and Uganda.
Alhassan Y; Twimukye A; Malaba T; Orrell C; Myer L; Waitt C; Lamorde M; Kambugu A; Reynolds H; Khoo S; Taegtmeyer M
BMC Health Serv Res; 2020 Aug; 20(1):705. PubMed ID: 32738918
[TBL] [Abstract][Full Text] [Related]
18. Provider perspectives on the acceptability and tolerability of dolutegravir-based anti-retroviral therapy after national roll-out in Uganda: a qualitative study.
Zakumumpa H; Kitutu FE; Ndagije HB; Diana NK; Ssanyu JN; Kiguba R
BMC Infect Dis; 2021 Dec; 21(1):1222. PubMed ID: 34876050
[TBL] [Abstract][Full Text] [Related]
19. Patient experiences of sexual dysfunction after transition to dolutegravir-based HIV treatment in mid-Western Uganda: a qualitative study.
Zakumumpa H; Kiguba R; Ndagije HB; Ategeka G; Ssanyu JN; Kitutu FE
BMC Infect Dis; 2022 Aug; 22(1):692. PubMed ID: 35971109
[TBL] [Abstract][Full Text] [Related]
20. Active Pharmacovigilance Project on the safety profile of Dolutegravir in Brazil.
Mendes JC; Ceccato MDGB; Reis AMM; Costa AMGD; Pantuzza LLN; Furtado Dos Santos S; Crepalde-Ribeiro K; Silveira MR
AIDS Care; 2023 May; 35(5):729-738. PubMed ID: 35578399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
